IDXX Shareholders' equity
Shareholders' equity at Idexx Laboratories rose to $1.6B in fiscal 2025, the highest in the 5 years reported, from $1.6B in 2024.
Stockholders' equity attributable to the parent, as filed.
SOURCE: us-gaap:StockholdersEquity · EDGAR CompanyFacts · CIK 874716 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$1.6B
FY2024 $1.6B
HIGH$1.6B FY2025
LOW$609M FY2022
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Shareholders' equity | Change |
|---|---|---|
| FY2025 | $1.6B | +$10M |
| FY2024 | $1.6B | +$111M |
| FY2023 | $1.5B | +$876M |
| FY2022 | $609M | $-81M |
| FY2021 | $690M | — |
More SAME DATA, OTHER VIEWS
Shareholders' equity across coverage → · IDXX company view →
Revenue · Net income · Operating cash flow · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.